Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of EG-Mirotin in Moderate to Severe Nonproliferative Diabetic Retinopathy
KCT0005124Phase 2Completed
- Sponsor
- EyeGene, Inc.
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EG-Mirotin in diabetic retinopathy (DR), sponsored by EyeGene, Inc. Started Aug 2020; status: completed.
02
Drugs
EG-Mirotin
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on KCT0005124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005124.